Jun 30, 2025 7:05am EDT Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
Jun 10, 2025 6:00am EDT Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
May 21, 2025 7:00am EDT Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting of Stockholders
May 14, 2025 7:15am EDT Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update
Apr 10, 2025 8:00am EDT Unicycive Presents New Patient-Level Data Underscoring Challenges Faced with Current Phosphate Binders and Highlighting the Potential of Oxylanthanum Carbonate to Address Barriers to Adherence for Patients with Hyperphosphatemia on Dialysis
Apr 01, 2025 7:00am EDT Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
Mar 31, 2025 7:00am EDT Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update
Mar 13, 2025 7:00am EDT Unicycive to Highlight Patient Reported Outcomes Data at Upcoming Medical Meetings Showing Oxylanthanum Carbonate Reduced Pill Burden and Improved Adherence in Treatment of Hyperphosphatemia
